The new ingredient expansion will commence commercial production early 2026.

Food and beverage private equity firm Arbor Investments announced its investment and partnership with the company in April 2019. The firm has a track record of driving transformative growth and innovation at its portfolio companies.

Beginning Sept. 1, the six-week trial is designed to further validate findings from the brands’ first consumer pilot study, which tested NZMP’s LactoB HN001 strain with 52 Floré customers to determine if there were any significant improvements in mental wellness and happiness.